Phase 1 Metastatic Breast Cancer trials recruiting now

All Metastatic Breast Cancer trials, every phase

Other phases for Metastatic Breast Cancer

Phase 1 Metastatic Breast Cancer trials

• A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
  NCT07081555 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 3 locations
• A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
  NCT06533332 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
  NCT07593820 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
  NCT06064812 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 22 locations
• A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
  NCT07002177 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
  NCT06678269 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
  NCT04872166 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer
  NCT07524855 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 6 locations
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
  NCT06110793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
  NCT06246968 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
  NCT06202261 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
  NCT04020575 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
  NCT06756932 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 105 locations
• Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
  NCT06900647 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
  NCT05029999 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 7 locations
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
  NCT05900895 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
  NCT05455619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• HER-2 B Cell Peptide Vaccine
  NCT06414733 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
  NCT03449238 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 90 Years · Sex: Female · 3 locations
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
  NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors
  NCT05544240 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
  NCT03591276 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.